Physician profile
Jacqueline Chan
NPI 1992931299
$12,241.44
in general payments reported to CMS, 2019-2025
25 companies · $7,625 in 2025
The $7,625 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $43.84 · 2021: $741 · 2022: $1,256 · 2023: $1,152 · 2024: $884 · 2025: $7,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,365 · Food and Beverage: $3,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,365.00 |
| Food and Beverage | $3,295.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $6,365.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $735.21 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $675.62 | 2021-2025 | Jardiance |
| Abbott Laboratories | $617.69 | 2019-2025 | Aveir |
| Novartis Pharmaceuticals Corporation | $574.68 | 2021-2024 | |
| Boston Scientific Corporation | $486.32 | 2024-2025 | General - Therapies, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $338.44 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $318.64 | 2023-2025 | Farxiga, Lokelma |
| Biotronik INC. | $288.21 | 2024-2025 | Biomonitor |
| Esperion Therapeutics, INC. | $244.64 | 2021-2022 | |
| Medtronic, INC. | $235.10 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $209.57 | 2022-2025 | Verquvo |
| Amgen INC. | $184.90 | 2022-2024 | Repatha |
| Heartflow, INC. | $144.94 | 2023 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $127.14 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.12 | 2022-2025 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Pfizer INC. | $94.14 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $92.85 | 2021-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.59 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $34.94 | 2023-2024 | Inpefa |
| Bard Peripheral Vascular, INC. | $32.95 | 2025 | Venclose Maven Catheter |
| Amarin Pharma, INC. | $23.08 | 2021 | |
| Bracco Diagnostics INC. | $3.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.